Posted by Michael Wonder on 09 Sep 2021
Insurance benefits for Pfizer’s heart drug Vyndamax uncertain
9 September 2021 - Pfizer’s Vyndamax (tafamidis), a treatment for transthyretin amyloid cardiomyopathy, got in the European Society of Cardiology’s list of recommended drugs for heart failure.
However, observers said it is uncertain whether the treatment would be reimbursable in Korea because of its high price.
